Andere Sprachen Monopar Therapeutics Inc.

Aktien

A2PQNF

US61023L1089

MNPR

Verzögert Nasdaq Andere Börsenplätze 18:34:38 16.07.2024			% 5 Tage	% 1. Jan.
0,7334 ^USD	+3,30 %		-1,03 %	+115,58 %

09.07.	Monopar Therapeutics Inc. gibt bekannt, dass der erste Patient in die Phase-1-Studie für das neuartige Radiopharmazeutikum MNPR-101-Zr aufgenommen wurde	CI
24.05.	Monopar Therapeutics ernennt Karthik Radhakrishnan zum CFO	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr	09.07.
Monopar Therapeutics Inc. Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr	09.07.
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24	25.06.
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24	25.06.
Monopar and NorthStar Amend & Extend Collaboration	11.06.
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting	10.06.
Monopar Therapeutics Names Karthik Radhakrishnan as CFO	24.05.
Monopar Announces CFO Succession	24.05.
Monopar Therapeutics Inc. Announces CFO Changes	24.05.
Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline	09.05.
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting	18.04.
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting	18.04.
Monopar Therapeutics Files Provisional Patent for New MNPR-101 Construct	16.04.
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings	16.04.
Monopar Therapeutics Inc. Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings	16.04.
North American Morning Briefing : Big Banks Kick -2-	12.04.
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients	10.04.
Monopar Therapeutics Inc Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients	10.04.
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments	28.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Monopar Therapeutics Inc.

Aktien

A2PQNF

US61023L1089

MNPR

Andere Sprachen

Filter